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Abstract
Background: In the course of surveillance of gastric cancer recurrence after curative resection, contrast
CT scan is used in general. However, new findings from CT scan are not always confirmatory for the
recurrence. In this case, we usually use short-term follow up strategy or therapeutic intervention with
clinical decision. Recently, the use of fusion Positron Emission Tomography/Computed Tomography (PET/
CT) is increasing. The purpose of this study is to evaluate the efficacy and usefulness of PET/CT for
detecting recurrence of gastric cancer after curative resection.
Methods: Fifty two patients who received curative resection of gastric cancer and had undergone PET/
CT and contrast CT for surveillance of recurrence until Dec 2006 in Seoul National University Hospital
were analyzed retrospectively. Recurrence of gastric cancer was validated by histologic confirmation (n =
17) or serial contrast CT follow up with at least 5 month interval (n = 35). McNemar's test and Fisher's
exact test were used to evaluate sensitivity and specificity of PET/CT and contrast CT.
Results: Of 52 patients, 38 patients were confirmed as recurrence. The sensitivity was 68.4% (26/38) for
PET/CT and 89.4% (34/38) for contrast CT (p = 0.057). The specificity was 71.4% (10/14) and 64.2% (9/
14), respectively (p = 1.0). In terms of the recurred sites, the sensitivity and specificity of PET/CT were
similar to those of contrast CT in all sites except peritoneum. Contrast CT was more sensitive than PET/
CT (p = 0.039) for detecting peritoneal seeding. Additional PET/CT on contrast CT showed no further
increase of positive predictive value regardless of sites. Among 13 patients whose image findings between
two methods were discordant and tissue confirmation was difficult, the treatment decision was made in 7
patients based on PET/CT, showing the final diagnostic accuracy of 42.8% (3/7).
Conclusion: PET/CT was as sensitive and specific as contrast CT in detection of recurred gastric cancer
except peritoneal seeding. However, additional PET/CT on contrast CT did not increase diagnostic
accuracy in detection of recurred gastric cancer. Further studies are warranted to validate the role of PET/
CT in detection of gastric cancer recurrence.
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Background
Gastric cancer is the fourth most common cancer world-
wide with approximately 930,000 new cases and 700,000
deaths per year [1]. The incidence of stomach cancer is
high in Asia, and it is the most common cancer in Korea
[2].
Early gastric cancer can be cured by complete resection,
while advanced disease often recurs in 40~60% of
patients after surgery [3,4]. To detect cancer recurrence,
various methods such as tumor markers, endoscopy or
imaging studies have been used. However, tumor markers
cannot localize the recurrence site and endoscopy cannot
detect extra-luminal recurrence [5].
At present, the most frequently used method for the detec-
tion of gastric cancer recurrence is contrast-enhanced
computed tomography (contrast CT) [5,6]. However, CT
has a notable limitation on diagnosis of malignancy
because it uses the size criteria. Therefore, it cannot reflect
the presence and viability of tumor precisely.
Fluorine 18 (18F) fluorodeoxyglucose (FDG) positron
emission tomography (PET), in contrast with CT, is a tool
that reflects cancer metabolism and cell biology. Recently,
FDG-PET combined with CT (Fusion PET/CT) has been
introduced and is expected to give us more precise ana-
tomical data with metabolic information. Fusion PET/CT
has been reported to be useful for staging of lung, colorec-
tal, breast, lymphoma, head and neck cancer and for
detecting recurrence of lung, colorectal, thyroid, and
breast cancer [7-14]. However, in contrast to the other
cancer, it has been reported that FDG uptake of gastric
cancer cell is relatively poor and the PET image has a lim-
itation on the detection of recurred gastric cancer [15,16].
The definitive method for diagnosis of gastric cancer
recurrence is the pathologic confirmation. However, get-
ting adequate tissues is often difficult because either
recurred tumor size is very small or it is deeply located or
too close to great vessels or organs for needle biopsy.
In clinical practice, it is hard to make treatment decision
when gastric cancer recurrence is suspicious in contrast CT
but tissue confirmation is difficult. In this case, additional
PET/CT could give us more information on the detection
of recurrence. Therefore, we conducted this study to eval-
uate efficacy and usefulness of PET/CT for the detection
and confirmation of recurred gastric cancer after curative
resection.
Methods
All information was collected and analyzed retrospec-
tively. We screened all the patients with gastric cancer who
received curative resection and had subsequently under-
gone contrast CT and PET/CT for the surveillance of recur-
rence between Apr. 2004 and Dec. 2006 in Seoul National
University Hospital. The patients were enrolled when the
cancer recurrence can be validated by tissue confirmation
or by the change of lesions on contrast CT follow up of at
least 5-month interval. Basically, all the patients had
undergone routine follow up with 3 to 6 month interval
after curative resection. Regardless of PET/CT, the diag-
nostic contrast CT scan was performed with 120 kVP, 120
mA, 5 mm thickness and 90 ml contrast media, which
were adjusted to body weight.
PET/CT Imaging
All scans were performed by PET/CT system (Philips
Gemini, DA best, Netherlands). The patients were asked
to fast for at least 4 hours before undergoing PET/CT and
555–740 MBq (15–20 mCi; 0.22 mCi/kg body weight) of
FDG was administered intravenously 1 hour prior to
imaging. CT was performed prior to PET, and the resulting
data were used to generate an attenuation correction map
for PET. Five-millimeter-thick sections were obtained at
50 mA (but adjusted for body thickness) and 120 kVp
from the skull base to the mid-thigh. Next, PET was per-
formed with a 5-min emission acquisition per imaging
level and the images were reconstructed.
Data analysis and Statistical methods
Fusion PET/CT was reviewed by a nuclear medicine physi-
cian who was aware of patients' information on clinical
findings and other imaging results. All lesions in PET/CT
and contrast CT were categorized as suspicious, negative
or equivocal lesions. Exo and Endo luminal recurrence
was categorized as locoregional recurrence and the other
patents of recurrence categorized as metastasis. In statisti-
cal analysis, the equivocal lesions were considered as neg-
ative lesions. Recurrence of gastric cancer was validated by
histologic confirmation or serial contrast CT follow up. It
was regarded as negative lesion when there was no change
between CT images of at least the 5 month interval. Over-
all and site-specific sensitivity, specificity, positive and
negative predictive values were calculated. McNemar's test
and Fisher's exact test were used to evaluate the efficacy of
PET/CT and contrast CT.
Ethics
The study protocol was reviewed and approved by the
institutional review board of Seoul National University
Hospital. The recommendations of the Declaration of
Helsinki for biomedical research involving human sub-
jects were also followed.
Results
Patients
52 patients in total were enrolled. Characteristics of the
patients are presented in Table 1. Forty three patients wereBMC Cancer 2009, 9:73 http://www.biomedcentral.com/1471-2407/9/73
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male. In terms of initial pathologic staging of initial gas-
tric cancer, 11.5% of the patients were in Ia, 21.1% in Ib,
19.2% in II, 25.0% in IIIa, 7.7% in IIIb and 15.4% in IV.
According to TNM stage, all stage IV patients revealed
TxN3M0 status. Adenocarcinoma was the predominant
histologic type of all resected specimens (90.4%, n = 47).
Among these patients, signet ring cell type was in 7.7% (n
= 4) patients.
Detection of Recurrence by fusion PET/CT and contrast 
CT
The interval between contrast CT and fusion PET/CT
ranged from 0 days to 45 days, with a median interval of
9 days. Among 52 patients, recurrence was confirmed in
38 patients by pathologic diagnosis or contrast CT follow
up of at least 5-month intervals (17 by pathologic confir-
mation, 35 by contrast CT follow up, Table 2). In 38
recurred cases, most of the recurrence sites were lymph
nodes(n = 20) and peritoneum (n = 15). Seven patients
had recurrence in remnant stomach or anastomosis sites
and six in the liver. Each one patient showed lung, subcu-
taneous and pleural metastasis. The sensitivity and specif-
icity according to recurrence site are described in Table 3.
The sensitivity and specificity between two methods were
not statistically significant except in detection of perito-
neal carcinomatosis. The contrast CT was more sensitive
than fusion PET/CT (p = 0.039) in detecting peritoneal
carcinomatosis.
Fusion PET/CT in addition to contrast CT
The overall positive predictive value of PET/CT on con-
trast CT was 89.7%. The site specific positive predictive
values are presented in Table 3 and Table 4. The addi-
tional fusion PET/CT did not increase the positive predic-
tive value statistically.
When the tissue confirmation is impossible, clinical deci-
sion and its final diagnosis by contrast CT image follow-
up is presented in figure 1. When the image findings
between the two methods were discordant, treatment
decision was made according to the PET/CT findings in 7
out of 13 cases (Figure 1 and Figure 2). But its final accu-
racy was 42.8% (3/7). Age and stage distribution in these
patients are presented in Table 5. Older and higher stage
patients had a tendency of increased recurrence of gastric
cancer regardless of results of the fusion PET/CT findings.
Discussion
Our study showed that PET/CT was as sensitive and spe-
cific as contrast CT in the detection of gastric cancer recur-
rence except in peritoneal carcinomatosis. Despite this
result, additional PET/CT on contrast CT did not give us
more accurate information to confirm cancer recurrence.
There are some reports about the role of FDG-PET or
fusion PET/CT in the evaluation of gastric cancer recur-
rence after curative resection, but the results are inconsist-
ent. Jadvar, et al. reports that FDG PET might be useful in
the post-therapy evaluation of recurrent disease[17]. Park,
et al. also suggested that PET/CT might have a role for
detecting recurrence in post-operative patients with gastric
cancer[18]. On the other hand, De Potter, et al. reported
that FDG-PET might not be suitable as a primary tool for
follow up due to its moderate accuracy[19].
In the aspect of sensitivity, fusion PET/CT alone was as
sensitive as contrast CT in most recurred sites according to
our study. However, the statistical significance is marginal
(p = 0.057) and the sensitivity of PET/CT showed inferior
tendency compared to contrast CT. Moreover, PET/CT was
inferior to contrast CT for detection of peritoneal recur-
rence, which corresponds with other previous reports
[10,20].
Table 1: Patient Characteristics
Characteristics No. (%)
Age Median 62
Range 33~80
Sex Male 43 (82.6)
Female 9 (17.3)
Pathologic stage Ia 6 (11.5)
Ib 11 (21.1)
II 10 (19.2)
IIIa 13 (25.0)
IIIb 4 (7.7)
IV 8 (15.4)
Pathology Adenocarcinoma 47 (90.4)
signet ring cell type 4 (7.7)
Unknown 1 (1.9)
Adjuvant chemotherapy Yes 35 (67.3)
No 17 (32.6)
Operation Total gastrectomy 26 (50)
Subtotal gastrectomy 26 (50)
Interval between CT and PET/CT Median 9 days
Range 0~45 days
Table 2: Recurrence and its specific site
Variables No.
Recurrence Yes 38
No 14
Pathological confirmation 17
Clinical confirmation by image 35
Recurrence site Locoregional recurrence 7
(Remnant stomach or anastomosis site)
Distant metastasis 37
Lymph-node 20
Liver 6
Other site (bone, skin, etc.) 3
Peritoneum 15BMC Cancer 2009, 9:73 http://www.biomedcentral.com/1471-2407/9/73
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These might be attributed to the method of CT validation
that could make the ability of contrast CT overestimated.
The other explanation would be due to the low metabolic
activity of recurred gastric cancer. The interpretation of
PET/CT is on both metabolic status of lesion and its ana-
tomical location on non-contrast CT. It is well known
FDG avidity depends on histologic type [15]. Signet ring
cell type or mucinous type is known to have low FDG
avidity. However, only a small portion of signet ring cell
cancer patients was included in the study population. And
the FDG avidity has not been known yet in recurred gas-
tric cancer.
In the aspect of the confirmation of recurrence, the bene-
fits of additional PET/CT on contast CT were low. This
may be because either additional PET/CT has little benefit
on prediction of gastric cancer recurrence or the study
population is too small to reveal the substantial benefits.
However, considering its high cost and small benefits, the
usefulness of additional PET/CT on contrast CT is unsatis-
factory.
Some reports showed that clinical information including
age, tumor size, histologic type, the number of involved
LN could be the risk factors for gastric cancer recur-
rence[21,22]. Our study also showed similar results of
increasing tendency of recurrence in higher stages regard-
less of results of fusion PET/CT (Table 5). Therefore, clin-
ical factors such pathological stage could be more helpful
to making treatment decision than PET/CT findings.
Our study has a few limitations. First, not all the recurred
cases were confirmed by pathologic diagnosis. the valida-
tion of recurrence by contrast CT may have caused physi-
cians to overestimate the detection rate of contrast CT. In
addition, 5-month interval may not be enough time to
confirm the absence of recurrence. Second, it is a retro-
spective study with small study population. In our data,
although about a half of total patients was early stage
patients, the recurrence rate was extremely high. However,
although the possibility of selection bas, recurrence to
non-recurrence ratio showed the increasing trend of recur-
rence rate as the stage get advanced in the patients with
discordant findings (Table 5).
Despite these deficiencies, our study has significance in
giving us evidence of the role of fusion PET/CT in post
operative surveillance and in the clinical decision-making
process. Further prospective studies enrolling large popu-
Table 3: Overall and site specific sensitivity and specificity of contrast CT and fusion PET/CT
Site Contrast CT Fusion PET/CT p-value
Overall Sensitivity (%) 89.4(34/38) 68.4(26/38) 0.057*
Specificity (%) 64.2(9/14) 71.4(10/14) 1.0*
PPV(%) 87.1(34/39) 86.6(26/30) 1.0
Remnant stomach or anastomosis site Sensitivity (%) 42.85(4/7) 100(7/7) 0.13*
Specificity (%) 95.5(43/45) 93.3(42/45) 1.0*
PPV(%) 60.0(3/5) 70.0(7/10) 1.0
Lymph-node Sensitivity (%) 90(18/20) 70(14/20) 0.21*
Specificity (%) 87.5(28/32) 96.8(31/32) 0.25*
PPV(%) 81.8(18/22) 93.3(14/15) 0.63
Peritoneum Sensitivity (%) 86.6(13/15) 46.6(8/15) 0.039*
Specificity (%) 91.9(34/37) 94.2(35/37) 1.0*
PPV(%) 82.3(13/16) 80.0(8/10) 1.0
Liver Sensitivity (%) 50.0(3/6) 66.6(4/6) 1.0*
Specificity (%) 100(46/46) 97.8(45/46) 1.0*
PPV(%) 100(3/3) 80.0(4/5) 1.0
*: calculated by McNemar's test
Table 4: Positive predictive value of contrast CT alone and of combination of the two methods
Recurrence site PPV(%) in Contrast CT +* PPV(%) in Fusion PETCT +* and contrast CT +* P-value
Overall recurrence 89.7(35/39) 88.0(22/25) 1.00
Lymph-node 81.8(18/22) 92.8(13/14) 0.62
Peritoneum 72.2(13/18) 85.7(6/7) 0.63
Remnant stomach or anastomosis 60.0(3/5) 75.5(3/4) 1.00
Liver 80.0(4/5) 100(3/3) 0.37
*: There is a lesion which is suspicious for recurrenceBMC Cancer 2009, 9:73 http://www.biomedcentral.com/1471-2407/9/73
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Treatment decision by findings from fusion PET/CT when tissue confirmation is impossible Figure 1
Treatment decision by findings from fusion PET/CT when tissue confirmation is impossible. When the image find-
ings between the two methods were discordant, treatment decision was made according to the PET/CT findings in 7 out of 13 
cases (Figure 1). But its final accuracy was 42.8% (3/7).
 
 
 
CT:Yes 
PETCT:No
CT:No 
PETCT:Yes
CT:Yes 
PETCT:Yes 
CT:No 
PETCT:No
G
G
G
G
G
G
G
G
Recurrence: Yes/No 
Image finding  Clinical decision Final diagnosis
G
Yes:5 
No: 6 
G
Yes:1 
No :1 
G
Yes:13
No: 0 
Yes:1 
No: 8 
G
Yes:5
No:0
Yes:4
No:2
Yes:1
No:0
Yes:0
No:1
Yes:11
No:2
Yes:0
No:0
Yes:1
No:0
Yes:0
No:8BMC Cancer 2009, 9:73 http://www.biomedcentral.com/1471-2407/9/73
Page 6 of 7
(page number not for citation purposes)
lations are needed to establish the role of fusion PET/CT
in detection of gastric cancer recurrence.
Conclusion
In conclusion, the role of fusion PET/CT in detection and
confirmation of recurrence of gastric cancer is limited.
Further well-designed prospective study is needed to
establish the role of fusion PET/CT in detection of gastric
cancer recurrence
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